tanimilast

Tanimilast is a novel, highly potent, and selective inhaled phosphodiesterase 4 (PDE4) inhibitor developed primarily for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and chronic bronchitis. It acts by inhibiting PDE4 isoforms A-D with high selectivity, leading to reduced inflammation in the airways. Tanimilast is formulated as a dry powder for inhalation via devices such as the NEXThaler. Its design allows for high retention in the lung and low systemic exposure, minimizing class-related side effects commonly seen with oral PDE4 inhibitors like roflumilast. The drug has demonstrated anti-inflammatory activity in preclinical models and clinical studies by modulating immune cell responses and downregulating pro-inflammatory mediators. Tanimilast is being developed by Chiesi Farmaceutici[1][2][4][5][7][8].

Brand names

CHF 6001 NEXThalerCHF6001 NEXThalerCHF-6001 NEXThaler

Other names

CHF6001 DPICHF-6001 DPICHF 6001 DPI